• In late February 2026, PROCEPT BioRobotics reported fourth quarter and full-year 2025 results showing higher sales but a larger net loss, and issued 2026 guidance calling for US$390 million to US$410 million in revenue, gross margin of about 65%, and a net loss of US$78,500,000 to US$91,500,000.
• Alongside this guidance, the company outlined 2027 targets, including 25% to 30% annual revenue growth and 68% to 70% gross margin, and soon after expanded its board to nine members by appointing former Shockwave Medical CFO Daniel Puckett as an independent director and Audit Committee member, reinforcing its financial and governance oversight.
• We’ll now examine how PROCEPT’s 2026–2027 growth and margin guidance, alongside Daniel Puckett’s board appointment, influences its investment narrative.

The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

PROCEPT BioRobotics Investment Narrative Recap

To own PROCEPT, you have to believe Aquablation can keep expanding from a relatively small installed base into a standard hospital treatment while the company manages ongoing losses. The key near term catalyst remains procedure and system growth supported by improved reimbursement, while the biggest risk is continued operating losses if growth slows. The 2026–2027 guidance and Daniel Puckett’s appointment do not fundamentally change these near term drivers, but they sharpen the focus on execution and financial discipline.

The most relevant update here is PROCEPT’s 2026 guidance for US$390 million to US$410 million in revenue, roughly 65% gross margin, and a sizeable net loss. This frames how much growth the company needs from HYDROS placements and Aquablation procedure volumes to narrow losses over time. Against that backdrop, adding an experienced ex CFO to the board and Audit Committee sits directly in the context of investors watching whether higher revenue can eventually translate into a more sustainable margin profile.

But while the growth story is appealing, investors should also be aware of how sustained net losses and reimbursement pressures could affect...

PROCEPT BioRobotics' narrative projects $563.8 million revenue and $70.4 million earnings by 2028.

Uncover how PROCEPT BioRobotics' forecasts yield a $32.50 fair value, a 29% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts, who were modeling revenue reaching about US$624 million and earnings of roughly US$77 million by 2028, are effectively betting that catalysts like broader Aquablation adoption will outweigh risks such as reimbursement pressure and dependence on one platform, yet this new guidance and board change could prompt those expectations to shift in very different directions, so it is worth comparing how your view stacks up against those more aggressive forecasts.

Explore 6 other fair value estimates on PROCEPT BioRobotics - why the stock might be worth just $32.45!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your PROCEPT BioRobotics research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free PROCEPT BioRobotics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate PROCEPT BioRobotics' overall financial health at a glance.

Curious About Other Options?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.